Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Psychophysiology of proactive and reactive relational aggression.

Murray-Close D, Holterman LA, Breslend NL, Sullivan A.

Biol Psychol. 2017 Dec;130:77-85. doi: 10.1016/j.biopsycho.2017.10.005. Epub 2017 Oct 18.

PMID:
29055714
2.

Corrigendum to ''Relational victimization and depressive symptoms: The role of autonomic nervous system reactivity in emerging adults'' [Int. J. Psychophysiol. 110C (2016) 119-127].

Holterman LA, Murray-Close DK, Breslend NL.

Int J Psychophysiol. 2017 Mar;113:46. doi: 10.1016/j.ijpsycho.2017.01.006. Epub 2017 Jan 19. No abstract available.

PMID:
28110968
3.

Relational victimization and depressive symptoms: The role of autonomic nervous system reactivity in emerging adults.

Holterman LA, Murray-Close DK, Breslend NL.

Int J Psychophysiol. 2016 Dec;110:119-127. doi: 10.1016/j.ijpsycho.2016.11.003. Epub 2016 Nov 5. Erratum in: Int J Psychophysiol. 2017 Mar;113:46.

PMID:
27825900
4.

Multivariate Analysis of the Risk Factors for First-Time Noncontact ACL Injury in High School and College Athletes: A Prospective Cohort Study With a Nested, Matched Case-Control Analysis.

Vacek PM, Slauterbeck JR, Tourville TW, Sturnick DR, Holterman LA, Smith HC, Shultz SJ, Johnson RJ, Tourville KJ, Beynnon BD.

Am J Sports Med. 2016 Jun;44(6):1492-501. doi: 10.1177/0363546516634682. Epub 2016 Mar 29.

5.

Geometric profile of the tibial plateau cartilage surface is associated with the risk of non-contact anterior cruciate ligament injury.

Beynnon BD, Vacek PM, Sturnick DR, Holterman LA, Gardner-Morse M, Tourville TW, Smith HC, Slauterbeck JR, Johnson RJ, Shultz SJ.

J Orthop Res. 2014 Jan;32(1):61-8. doi: 10.1002/jor.22434. Epub 2013 Sep 30.

6.

Response to methodological concerns.

Goetschius J, Smith HC, Vacek PM, Holterman LA, Tourville TW, Slauterbeck J, Johnson RJ, Beynnon BD, Shultz SJ.

Am J Sports Med. 2013 Jan;41(1):NP3-6. No abstract available.

7.

Gender related differences in predictors of vascular complications: role of vessel size and BMI.

Ahmed B, Lischke S, De Sarno M, Holterman LA, Straight F, Dauerman HL.

J Thromb Thrombolysis. 2013 Jul;36(1):84-90. doi: 10.1007/s11239-012-0847-y.

PMID:
23239168
8.

Application of a clinic-based algorithm as a tool to identify female athletes at risk for anterior cruciate ligament injury: a prospective cohort study with a nested, matched case-control analysis.

Goetschius J, Smith HC, Vacek PM, Holterman LA, Shultz SJ, Tourville TW, Slauterbeck J, Johnson RJ, Beynnon BD.

Am J Sports Med. 2012 Sep;40(9):1978-84. doi: 10.1177/0363546512456972. Epub 2012 Aug 9.

9.

A prospective evaluation of the Landing Error Scoring System (LESS) as a screening tool for anterior cruciate ligament injury risk.

Smith HC, Johnson RJ, Shultz SJ, Tourville T, Holterman LA, Slauterbeck J, Vacek PM, Beynnon BD.

Am J Sports Med. 2012 Mar;40(3):521-6. doi: 10.1177/0363546511429776. Epub 2011 Nov 23.

10.

Angiographic predictors of vascular complications among women undergoing cardiac catheterization and intervention.

Ahmed B, Lischke S, Holterman LA, Straight F, Dauerman HL.

J Invasive Cardiol. 2010 Nov;22(11):512-6.

11.

Adenovirus serotype 5 infects human dendritic cells via a coxsackievirus-adenovirus receptor-independent receptor pathway mediated by lactoferrin and DC-SIGN.

Adams WC, Bond E, Havenga MJ, Holterman L, Goudsmit J, Karlsson Hedestam GB, Koup RA, Loré K.

J Gen Virol. 2009 Jul;90(Pt 7):1600-10. doi: 10.1099/vir.0.008342-0. Epub 2009 Mar 12.

PMID:
19282435
12.

Serum-free transient protein production system based on adenoviral vector and PER.C6 technology: high yield and preserved bioactivity.

Havenga MJ, Holterman L, Melis I, Smits S, Kaspers J, Heemskerk E, van der Vlugt R, Koldijk M, Schouten GJ, Hateboer G, Brouwer K, Vogels R, Goudsmit J.

Biotechnol Bioeng. 2008 Jun 1;100(2):273-83. doi: 10.1002/bit.21757.

PMID:
18512821
13.

Differential antigen requirements for protection against systemic and intranasal vaccinia virus challenges in mice.

Kaufman DR, Goudsmit J, Holterman L, Ewald BA, Denholtz M, Devoy C, Giri A, Grandpre LE, Heraud JM, Franchini G, Seaman MS, Havenga MJ, Barouch DH.

J Virol. 2008 Jul;82(14):6829-37. doi: 10.1128/JVI.00353-08. Epub 2008 Apr 30.

14.

Impact of recombinant adenovirus serotype 35 priming versus boosting of a Plasmodium falciparum protein: characterization of T- and B-cell responses to liver-stage antigen 1.

Rodríguez A, Goudsmit J, Companjen A, Mintardjo R, Gillissen G, Tax D, Sijtsma J, Weverling GJ, Holterman L, Lanar DE, Havenga MJ, Radosevic K.

Infect Immun. 2008 Apr;76(4):1709-18. doi: 10.1128/IAI.01614-07. Epub 2008 Jan 22.

15.

High-level expression from two independent expression cassettes in replication-incompetent adenovirus type 35 vector.

Vogels R, Zuijdgeest D, van Meerendonk M, Companjen A, Gillissen G, Sijtsma J, Melis I, Holterman L, Radosevic K, Goudsmit J, Havenga MJ.

J Gen Virol. 2007 Nov;88(Pt 11):2915-24.

PMID:
17947512
16.

Increased immunogenicity of recombinant Ad35-based malaria vaccine through formulation with aluminium phosphate adjuvant.

Ophorst OJ, Radosević K, Klap JM, Sijtsma J, Gillissen G, Mintardjo R, van Ooij MJ, Holterman L, Companjen A, Goudsmit J, Havenga MJ.

Vaccine. 2007 Aug 29;25(35):6501-10. Epub 2007 Jun 29.

PMID:
17646036
17.

Myeloid and plasmacytoid dendritic cells are susceptible to recombinant adenovirus vectors and stimulate polyfunctional memory T cell responses.

Loré K, Adams WC, Havenga MJ, Precopio ML, Holterman L, Goudsmit J, Koup RA.

J Immunol. 2007 Aug 1;179(3):1721-9.

18.

Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D.

Abbink P, Lemckert AA, Ewald BA, Lynch DM, Denholtz M, Smits S, Holterman L, Damen I, Vogels R, Thorner AR, O'Brien KL, Carville A, Mansfield KG, Goudsmit J, Havenga MJ, Barouch DH.

J Virol. 2007 May;81(9):4654-63. Epub 2007 Feb 28.

19.

Expression and immunogenicity of the Plasmodium falciparum circumsporozoite protein: the role of GPI signal sequence.

Ophorst OJ, Radosević K, Ouwehand K, van Beem W, Mintardjo R, Sijtsma J, Kaspers J, Companjen A, Holterman L, Goudsmit J, Havenga MJ.

Vaccine. 2007 Feb 9;25(8):1426-36. Epub 2006 Nov 7.

PMID:
17161889
20.

Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa.

Thorner AR, Vogels R, Kaspers J, Weverling GJ, Holterman L, Lemckert AA, Dilraj A, McNally LM, Jeena PM, Jepsen S, Abbink P, Nanda A, Swanson PE, Bates AT, O'Brien KL, Havenga MJ, Goudsmit J, Barouch DH.

J Clin Microbiol. 2006 Oct;44(10):3781-3.

21.

Generation of a novel replication-incompetent adenoviral vector derived from human adenovirus type 49: manufacture on PER.C6 cells, tropism and immunogenicity.

Lemckert AA, Grimbergen J, Smits S, Hartkoorn E, Holterman L, Berkhout B, Barouch DH, Vogels R, Quax P, Goudsmit J, Havenga MJ.

J Gen Virol. 2006 Oct;87(Pt 10):2891-9.

PMID:
16963747
22.

Novel replication-incompetent adenoviral B-group vectors: high vector stability and yield in PER.C6 cells.

Havenga M, Vogels R, Zuijdgeest D, Radosevic K, Mueller S, Sieuwerts M, Weichold F, Damen I, Kaspers J, Lemckert A, van Meerendonk M, van der Vlugt R, Holterman L, Hone D, Skeiky Y, Mintardjo R, Gillissen G, Barouch D, Sadoff J, Goudsmit J.

J Gen Virol. 2006 Aug;87(Pt 8):2135-43.

PMID:
16847108
23.

Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity.

Roberts DM, Nanda A, Havenga MJ, Abbink P, Lynch DM, Ewald BA, Liu J, Thorner AR, Swanson PE, Gorgone DA, Lifton MA, Lemckert AA, Holterman L, Chen B, Dilraj A, Carville A, Mansfield KG, Goudsmit J, Barouch DH.

Nature. 2006 May 11;441(7090):239-43. Epub 2006 Apr 16.

PMID:
16625206
24.

Immunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice.

Ophorst OJ, Radosević K, Havenga MJ, Pau MG, Holterman L, Berkhout B, Goudsmit J, Tsuji M.

Infect Immun. 2006 Jan;74(1):313-20.

25.

Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity.

Lemckert AA, Sumida SM, Holterman L, Vogels R, Truitt DM, Lynch DM, Nanda A, Ewald BA, Gorgone DA, Lifton MA, Goudsmit J, Havenga MJ, Barouch DH.

J Virol. 2005 Aug;79(15):9694-701.

26.

Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5.

Holterman L, Vogels R, van der Vlugt R, Sieuwerts M, Grimbergen J, Kaspers J, Geelen E, van der Helm E, Lemckert A, Gillissen G, Verhaagh S, Custers J, Zuijdgeest D, Berkhout B, Bakker M, Quax P, Goudsmit J, Havenga M.

J Virol. 2004 Dec;78(23):13207-15.

27.
28.

Characteristics of a pathogenic molecular clone of an end-stage serum-derived variant of simian immunodeficiency virus (SIV(F359)).

Holterman L, Dubbes R, Mullins J, Learn G, Niphuis H, Koornstra W, Koopman G, Kuhn EM, Wade-Evans A, Rosenwirth B, Haaijman J, Heeney J.

J Virol. 2001 Oct;75(19):9328-38.

29.

The rate of progression to AIDS is independent of virus dose in simian immunodeficiency virus-infected macaques.

Holterman L, Niphuis H, Koornstra W, Dubbes R, ten Haaft P, Heeney JL.

J Gen Virol. 2000 Jul;81(Pt 7):1719-26.

PMID:
10859377
30.

A strategy for cloning infectious molecular clones of retroviruses from serum or plasma.

Holterman L, Dubbes R, Mullins J, Haaijman J, Heeney J.

J Virol Methods. 2000 Jan;84(1):37-48.

PMID:
10644085
31.

Specific passage of simian immunodeficiency virus from end-stage disease results in accelerated progression to AIDS in rhesus macaques.

Holterman L, Niphuis H, ten Haaft PJ, Goudsmit J, Baskin G, Heeney JL.

J Gen Virol. 1999 Dec;80 ( Pt 12):3089-97.

PMID:
10567639
32.

Direct amplification and cloning of up to 5-kb lentivirus genomes from serum.

Holterman L, Mullins JI, Haaijman JJ, Heeney JL.

Biotechniques. 1996 Aug;21(2):312-9.

33.

Vaccine protection and reduced virus load from heterologous macaque-propagated SIV challenge.

Heeney JL, Holterman L, ten Haaft P, Dubbes R, Koornstra W, Teeuwsen V, Bourquin P, Norley S, Niphuis H.

AIDS Res Hum Retroviruses. 1994;10 Suppl 2:S117-21.

PMID:
7865285
34.

Lymphoproliferative disorders developing after transplantation and their relation to simian T-cell leukemia virus infection.

Stevens HP, Holterman L, Haaksma AG, Jonker M, Heeney JL.

Transpl Int. 1992;5 Suppl 1:S450-3.

PMID:
14621843
35.

Molecular cloning of the gene for the E1 alpha subunit of the pyruvate dehydrogenase complex from Saccharomyces cerevisiae.

Steensma HY, Holterman L, Dekker I, van Sluis CA, Wenzel TJ.

Eur J Biochem. 1990 Aug 17;191(3):769-74.

Supplemental Content

Loading ...
Support Center